KRIYA-839 / Kriya Therap - LARVOL DELTA

THE PROGRESS STUDY: PHASE 1/2 CLINICAL TRIAL OF KRIYA-839, A NOVEL AAV GENE THERAPY FOR ADULTS WITH TYPE 1 DIABETES (ATTD 2026) - "Conclusion The PROGRESS study represents the first ever clinical trial of an AAV gene therapy for the treatment of T1D. If successful, this one-time therapy could offer the potential for sustained improvement in glycemic control over long periods of time without the need for chronic immunosuppression."

Clinical • First-in-human • Gene therapy • P1/2 data • Diabetes • Gene Therapies • Metabolic Disorders • Type 1 Diabetes Mellitus

Characterization of KRIYA-839, an AAV-based Gene Therapy Providing Insulin and Glucokinase, in Streptozotocin-induced Diabetic Mice (ASGCT 2025) - "This study demonstrates the potential of KRIYA-839 for T1D and lays the foundation for future clinical studies. Disease Focus of Abstract:Diabetes"

Gene therapy • Preclinical • Diabetes • Gene Therapies • Hypoglycemia • Immunology • Infectious Disease • Metabolic Disorders • Oncology • Type 1 Diabetes Mellitus • SLC2A4

Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025 (GlobeNewswire) - "Kriya Therapeutics, Inc...announced thirteen presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will be held May 13 to 17, 2025 in New Orleans, LA."

PK/PD data • Preclinical • Diabetes • Immunology • Macular Degeneration • Thyroid Eye Disease